Type 2 Diabetes > ITCA 650
~318 spots leftby Apr 2026

A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650

Recruiting in Palo Alto (17 mi)
+39 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Waitlist Available
Sponsor: Intarcia Therapeutics
No Placebo Group
Pivotal Trial (Near Approval)
Prior Safety Data

Trial Summary

What is the purpose of this trial?

Phase 3 study to Evaluate cardiovascular outcomes in patients with type 2 diabetes treated with ITCA 650.

Research Team

Eligibility Criteria

Inclusion Criteria

HBA1c > 6.5%
History of coronary, cerebrovascular or peripheral artery disease

Treatment Details

Interventions

  • ITCA 650 (Other)
  • ITCA placebo (Other)
Participant Groups
2Treatment groups
Experimental Treatment
Group I: ITCA placeboExperimental Treatment1 Intervention
Group II: ITCA 650 60 mcg/dayExperimental Treatment1 Intervention
ITCA 650 is exenatide in DUROS

Find a Clinic Near You

Who Is Running the Clinical Trial?

Intarcia Therapeutics

Lead Sponsor

Trials
21
Recruited
8,100+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top